Program
HSK46256
A development code.
Its studies are led by Haisco Pharmaceutical Group.
Furthest: phase 1, since Jun 29, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 11 open or running | phase 1since Jun 29, 2026 | Jun 29, 2026 | Dec 30, 2028phase 1 · NCT07695142 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 29, 2026First study: phase 1 study in Advanced Solid Tumor (Phase 1)First studyNCT07695142 · 275 planned · China
Ahead
- Dec 30, 2028Primary completion: phase 1 study in Advanced Solid Tumor (Phase 1)NCT07695142
TargetBeta
PARP1 →read by rule
“This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HSK46256 tablets, a selective PARP1 inhibitor, in patients with advanced solid tumors.”study text, by rule · the study
Other programs on PARP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olaparibrule | AstraZeneca | phase 4 | 78 |
| niraparibrule | GlaxoSmithKline | phase 4 | 43 |
| saruparibrule | AstraZeneca | phase 3 | 14 |
| senaparibrule | impact-therapeutics-inc | phase 2 | 12 |
| nesuparibrule | Jeil Pharmaceutical | phase 2 | 4 |
| palacaparib | AstraZeneca | phase 2 | 3 |
| PARP1 Inhibitor HS-10502rule | Hansoh Pharmaceutical Group | phase 1 | 2 |
| DM5167rule | digmbio | phase 1 | 1 |
| TQB3122 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07695142Advanced Solid Tumor (Phase 1) · China | 1 | Recruiting | Dec 30, 2028 | 275 |
How it is read
Names in the registry
- “HSK46256”, 1 entry
Codes read as this program: HSK46256.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.